Eternalcreative | Istock | Getty Images
Miracle medicine, weight problems therapies and thin jabs. Call them what you’ll, few medicine have had a extra transformative impact on Wall Street and waistlines over latest a long time than GLP-1s.
Familiarly identified underneath the model names Wegovy and Zepbound, Glucagon-like peptide-1 (GLP-1) receptor agonists are a category of remedy used to deal with sort 2 diabetes and weight problems by mimicking hormones produced in the intestine to suppress an individual’s urge for food and regulate blood sugar.
Since Wegovy first obtained U.S. approval to deal with weight problems in 2021, and Zepbound in 2023, the medicine have skyrocketed to fame, bringing long-sought options to tens of thousands and thousands of sufferers and supercharging the progress of respective mum or dad firms Novo Nordisk and Eli Lilly.
Obesity is a major danger consider lots of the main causes of loss of life. As new functions — and rivals — for the medicine come to gentle, Wall Street is betting massive on the burgeoning business, with estimates suggesting it might be value upwards of $100 billion by 2030.
Sophie Dix, head of medical affairs at MedExpress, mentioned the medicine’ potential novel functions have been “unexpected and promising,” with new indications for Psoriasis, Asthma, Chronic kidney illness, fatty liver illness, obstructive sleep apnoea, Polycystic Ovary Syndrome (PCOS), weight problems–associated cancers, Alzheimer’s and Parkinson’s illness.
Experts say the wide-ranging swathe of functions may open up doubtlessly sweeping implications for each well being outcomes and the economy.
Sparking financial progress
The present price of the medicine is sizeable, with the U.S. listing costs for a month’s provide of Lily’s Zepbound or Novo’s Wegovy starting from $1,079.77 to $1,349.02. Estimates from the Jama Health Forum counsel that U.S. Medicare protection of GLP-1s would enhance internet spending underneath the retiree well being program by $47.7 billion alone over the subsequent 10 years.
But the anticipated well being and financial outcomes are vital, too. Poor well being from weight problems and weight problems associated diseases weigh considerably on well being programs and total productiveness, together with by misplaced hours labored, early loss of life and casual caregiving.
Goldman Sachs estimates that GLP-1s may increase U.S. gross home product (GDP) by 0.4% through elevated productiveness and healthcare financial savings, assuming a baseline adoption of 30 million customers, in accordance with a 2024 report. An estimated 2% of U.S. adults — roughly 5 million individuals — have been taking GLP-1s as of a May 2025 report from non-profit Fair Health.
“Poor health imposes significant economic costs that would diminish if health outcomes improve,” Goldman Sachs analysts wrote in the report. “Academic studies find that obese individuals are both less likely to work … and less productive when they do.”
Meanwhile in Denmark, Wegovy-maker Novo Nordisk’s market capitalization eclipsed that of its dwelling nation’s whole GDP in 2024, and the nation’s giant and rising weight reduction drug business continues to have an outsized contribution to the economy.
As such, GLP-1s’ perceived potential — each in weight problems and diabetes remedy in addition to different well being situations — is seen sparking a brand new period of drug innovation, with Dix describing the attainable influence as “profound” for each future drug growth and new job creation.
Pharma giants together with AstraZeneca, Pfizer, Roche and Zealand Pharma are already creating competitor weight problems therapies, whereas many extra are increasing into metabolic and cardiometabolic illness analysis, and growth with weight problems as an entry level.
“It’s also important to keep in mind that first-in-class is rarely best-in-class. Follow-up drugs may be more powerful, more selective and with side effects ironed out or controlled with combination therapies. As a result, I would anticipate there to be improvements in efficacy, tolerability (fewer side effects) and convenience,” Dix mentioned.
Shifting meals habits
The intensive adoption of weight reduction medicine can be seen having main results on client spending patterns, significantly given the larger propensity for discretionary spending amongst many wealthier, self-funded customers.
“These consumers which are the most likely to take the drugs are also the ones that are responsible for a lot of consumption,” Aljoscha Janssen, assistant professor of economics at the Singapore Management University, mentioned through video name.
Unsurprisingly, the most seen influence of that at current is on the meals and beverage business. A 2024 Cornell University examine discovered that households with no less than one GLP-1 consumer minimize their grocery spend by 5.3% inside six months of adoption, with that price rising to eight.2% amongst higher-income households.
Penpak Ngamsathain | Moment | Getty Images
Those who remained on the medicine for six to 12 months continued to scale back their spend, although at much less dramatic charges, in accordance with up to date findings as of Aug. 2025. Meanwhile, those that discontinued the remedy returned to pre-adoption spending ranges — and, in some instances, rose above them.
Processed snack meals equivalent to chips, cookies and bakery gadgets noticed the largest cutbacks in spending, although reductions have been additionally famous throughout many staple classes. Only modest will increase have been recorded in more healthy gadgets, equivalent to yoghurt and recent fruit.
“The pattern is less about switching to ‘better’ foods and more about simply buying less food,” Jura Liaukonyte, professor of promoting and utilized economics at Cornell University and considered one of the report’s authors, informed CNBC through electronic mail.
Eli Lilly and Novo Nordisk
That may have vital implications for fast-paced client items (FMCG) companies, in addition to meals producers extra broadly. Indeed, some firms equivalent to Nestle and Danone have already begun launching new traces to range their product base and cater for shifting developments. These embrace excessive protein meals, smaller portion sizes and meals geared toward encouraging muscle retention.
“Manufacturers and retailers have very specific customers who buy very specific products,” Janssen mentioned. Typically, that is good for constructing model loyalty, he famous. “But when you have something that is changing the behavior of consumers, as a weight loss drug could do, this becomes pretty risky.”
Booze, garments, eating places and journey
The influence of the medicine may go nicely previous meals, too. GLP-1s management urge for food by targeting the brain’s reward pathway, and particularly the launch of dopamine to the a part of the mind linked to motivation, pleasure and reward. As such, early research counsel functions for the drug in the remedy of addictions.
“This modulation of the brain’s reward system extends beyond food, with early evidence suggesting benefits in reducing alcohol misuse, drug dependence, and even gambling,” Dix mentioned.
That has raised considerations for the producers of leisure stimulants like alcohol and tobacco. Cornell’s examine, for its half, famous no “meaningful” change in alcohol purchases amongst GLP-1 customers, mirroring different literature which factors to a possible discount in depth of consuming episodes moderately than frequency.
Spirits big and Johnnie Walker-maker Diageo mentioned earlier this month that it was “keeping a close eye” on GLP-1s however indicated that the influence to this point “has not been significant.”
Sorrasak Jar Tinyo | Moment | Getty Images
Elsewhere, the ramifications for different sectors seem wide-reaching. Analysts have posited shifts in retail spending — together with better activewear gross sales to decreased outsized demand — and fuel-savings for airways from lighter passenger hundreds. Gyms and private trainers may additionally see an uptick in demand, whereas trip resorts capitalize on new alternatives to cater for extra lively and health-oriented guests.
More instantly, eateries from fast-food chains to upscale eating places are reckoning with a brand new client panorama and doubtlessly decrease future demand.
“In the short run, yes, these drugs reduce spending at fast-food and quick-service restaurants. At a national level, this already translates into billions of dollars in reduced sales,” Liaukonyte mentioned.
“But the long-term picture is far less certain. The ultimate impact will depend heavily on whether people stay on the drugs consistently and for how long — and we simply don’t know that yet.”
A two-tier society
For all the attainable financial outcomes of GLP-1s, questions nonetheless stay about the societal implications of a drug with such a visual bodily marker.
While remedy has rolled out quickly in only a brief variety of years, accessibility stays restricted even in developed international locations, with many nationwide well being programs proscribing coated entry to sufferers with excessive weight problems and related well being situations. Meantime, take up has surged amongst paid clients who are keen — and in a position — to fork out personally for the drug.
“We know that there are huge social determinants of health and that obesity is higher in areas of lower income,” mentioned Dix, who recommended public well being our bodies’ adoption of the medicine however lamented their usually “woefully slow” rollout.
“This creates the risk of a two tier society in which only those that can afford it can access these life-changing medications.”
Drug makers have already gone a way in reducing prices, with that pattern set to proceed amid coverage modifications, together with President Donald Trump’s U.S. drug pricing order, and elevated market competitors. Still, with protracted use of the medicine set to weigh on public and private purse strings, analysts warn that policymakers should be aware of exacerbating socioeconomic divisions.
“If rich people get a pharmaceutical which makes them skinny, then the already evident inequality in terms of weight — which is already highly correlated with income and education — further intensifies,” Janssen mentioned.
“That is something which for sure would have a negative impact on broader society,” he added.